Inflammatory models of neurodegeneration suggest that higher circulating levels of inflammation can lead to cognitive decline. Despite established independent associations between greater body mass, increased inflammation, and cognitive decline, no prior research has explored whether markers of systemic inflammation might mediate the association between body mass and changes in cognitive functioning. To test such a model, we used two longitudinal subsamples (ns = 9066; 12,561) of aging adults from the English Longitudinal Study of Ageing (ELSA) study, which included two cognitive measures components of memory and executive functioning, as well as measurements of body mass and systemic inflammation, assessed via C-reactive protein (CRP). Greater body mass was indirectly associated with declines in memory and executive functioning over 6 years via relatively higher levels of CRP. Our results suggest that systemic inflammation is one biologically plausible mechanism through which differences in body mass might influence changes in cognitive functioning among aging adults.
Introduction
Preserved cognitive functioning is an important marker of quality of life among aging adults (Abrahamson et al., 2013; Nys et al., 2006) . Although cognitive decline is linked with aging, the rate of this decline in aging is highly variable (Fillit et al., 2002; Park et al., 2003) and can depend on a variety of individual differences, including exaggerated inflammatory responses (Tegeler et al., 2016; Teunissen et al., 2003; Yaffe et al., 2003) and elevated body mass (Memel et al., 2016) , as well as a host of psychosocial and health behavior variables (e.g., social engagement, physical health, physical activity, and depression; Bourassa et al., 2015) . With the rate of adults that are 65 years and older rising relative to the overall population in almost all developed countries (Restrepo and Rozental, 1994) , understanding what risk factors are associated with cognitive decline is essential for developing interventions to promote successful aging. To explore one potential pathway that might explain risk for cognitive decline among aging adults, we examined the associations among body mass, inflammation, and change in cognition over 6 years in a nationally representative sample of older adults.
Inflammation and cognitive decline
Inflammation is one biologically-mediated pathway that might explain individual differences in cognitive decline among aging adults. Higher systemic inflammation levels are associated with cognitive decline in normative aging populations (Tegeler et al., 2016; Teunissen et al., 2003; Yaffe et al., 2003) , as well as in clinical samples experiencing age-related neurological disorders (Perry et al., 2007) . Inflammatory models of neurodegeneration propose that systemic inflammation is negatively associated with cognition via increases in neuro-inflammation. Inflammatory cytokines -including Tumor Necrosis Factor(TNF)a, Interleukin (IL)-1b, and IL-6 -secreted by microglia in the brain likely establish and maintain neuro-inflammation (Glass et al., 2010) , which can lead to neuronal apoptosis over the long-term (McCoy and Tansey, 2008; Simi et al., 2007) , and inhibit neurogenesis in adults (Ekdahl et al., 2003) . Systemic inflammation in the periphery is tied to neuro-inflammation in neurodegenerative disorders (Perry, 2004) , as well as in aging populations more generally (Perry, 2010) . For example, IL-6 and C-reactive protein (CRP) assessed in the periphery are associated with changes in brain morphology and cognitive decline in midlife (Marsland et al., 2015) . As a result, individual differences in systemic inflammation may explain a portion of the variability in cognitive decline among aging adults. 
